BMS Looks To Utilize Cash Reserves To Break Into Japan's Top Tier
This article was originally published in PharmAsia News
TOKYO - Bristol-Myers Squibb Co. expects to stop a five-year skid in Japan sales by the end of FY2011, and CEO Lamberto Andreotti said the company will utilize its large cash reserves for new business development opportunities in an effort to become a top 20 company in Japan
You may also be interested in...
In 2011, Bristol-Myers Squibb stopped a five-year slide in Japan, turning sales into the black for the first time since 2005.
If you missed some of the highlights of 2011, here’s your opportunity to check out some of our favorite stories from the year, as chosen by the editors of PharmAsia News.
Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
In a transaction that involves no cash moving in either direction, Bristol-Myers Squibb has expanded its territorial rights to an oncology antibody acquired in its 2009 purchase of Medarex, while Ono Pharmaceutical gets co-development and co-commercialization rights to rheumatoid arthritis drug Orencia (abatacept) in Japan